We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellzome to Study Epigenetic Factors with Neusentis
News

Cellzome to Study Epigenetic Factors with Neusentis

Cellzome to Study Epigenetic Factors with Neusentis
News

Cellzome to Study Epigenetic Factors with Neusentis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cellzome to Study Epigenetic Factors with Neusentis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellzome has announced a joint project with Pfizer’s Pain & Sensory Disorders and Regenerative Medicine unit ‘Neusentis’, to characterize epigenetic factors involved in stem cell differentiation using Cellzome’s Episphere™ technology.

The aim of the project is to shed light on the epigenetic mechanisms involved in the regulation of stem cell differentiation.

Pfizer will provide its know-how in stem cell handling and regenerative medicine, while Cellzome will apply its world-leading chemoproteomics platform to chart the changes of epigenetic factors during stem cell differentiation.

Tim Edwards, CEO of Cellzome said: “This is a very exciting collaboration in an emerging area of science. Cellzome can monitor epigenetic factors in their natural complexes directly throughout stem cell differentiation. We look forward to working with Pfizer to gain fundamental insights into epigenetic regulation which may be instrumental for any therapeutic applications in regenerative medicine.”

Advertisement